dexamethasone

P=N/A, N=150, Completed, Assiut University | Not yet recruiting --> Completed

P=N/A, N=100, Completed, Zagazig University | Enrolling by invitation --> Completed | Trial primary completion date: Sep 2025 --> Dec 2025

Serial assessments were performed before and during treatment with bortezomib and dexamethasone for MM, and later with daunorubicin/cytarabine for AML. It demonstrates the earliest events in pDC-AML evolution. Furthermore, the immature immunophenotype raises the question of appropriate treatment, since a diagnosis of acute undifferentiated leukemia can be established.

P=N/A, N=35, Recruiting, University of Louisville | Not yet recruiting --> Recruiting

P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

P4, N=22, Not yet recruiting, Cairo University

TAR included an NK1 receptor antagonist, a 5-HT3 receptor antagonist (or fixed netupitant/palonosetron combination), and dexamethasone. There was a trend toward a longer median time to T-DXd dose reduction in the TAR group (15.7 vs. 3.9 months; P = 0.183). These findings suggest that upfront TAR may help maintain the dosing of T-DXd in patients with HER2-positive or HER2-low ABC.

Lenalidomide, bortezomib, and dexamethasone, demonstrate significant clinical efficacy in treating multiple myeloma.

P2, N=70, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P2, N=46, Completed, University of Chicago | Trial completion date: Mar 2027 --> Dec 2025 | Active, not recruiting --> Completed

P=N/A, N=30, Not yet recruiting, The Hospital for Sick Children

P2, N=100, Recruiting, C4 Therapeutics, Inc. | Not yet recruiting --> Recruiting